Albany Molecular Research (AMRI) Reports Q4 Loss of $0.19; Guides Contract Revs
Tweet
Share
E-mailGet Alerts AMRI Hot Sheet
Price: $21.74 --0%
Financial Fact:
Other (expense) income, net: -549K
Today's EPS Names:
FWDI, GO, BATL, More
Financial Fact:
Other (expense) income, net: -549K
Today's EPS Names:
FWDI, GO, BATL, More
Join SI Premium – FREE
Albany Molecular Research (NASDAQ: AMRI) reported Q4 EPS of ($0.19), versus ($0.16) reported last year. Revenue for the quarter came in at $46.6 million, versus $48.6 million reported last year.
Sees Q1 2012 contract revenue of $37-$40 million.
Sees FY2012 contract revenue of $176-$186 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Sees Q1 2012 contract revenue of $37-$40 million.
Sees FY2012 contract revenue of $176-$186 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okta upgraded as AI security opportunity boosts outlook
- Digital Brands Group forecasts positive cash flow starting in September
- Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
